$FTRE

Thakral Anshul sold $2.0M of FTRE

Thakral Anshul (Chief Executive Officer) sold 111,857 shares of Fortrea Holdings Inc. (FTRE) at an average of $18.12 ($18.06–$18.17, $2.03M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Thakral Anshul
Published Aug 7, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FTRE
Neutral
medium confidence
Mentioned
$FTRE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price range, total value) and post-transaction holdings.

02

Market read

Insider selling can move sentiment at the margin, but this filing lacks any accompanying fundamental update.

03

What to watch

The filing does not state motives; traders should compare with prior insider activity and the stock’s broader news flow rather than assume bearish fundamentals.

Relevance 6/10Novelty 3/10Timing: filed Aug 7, after Aug 6 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Fortrea Holdings Inc.

Company-level read

Ticker impact

$FTRENeutralMedium confidence
Context

Fortrea CEO Thakral Anshul sold about 111,857 shares in open-market trades at roughly $18.06 to $18.17, totaling $2.03M.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no company-specific news like earnings, guidance, or contracts.

Market effects

Minimal, as the disclosure is company-specific insider trading without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan could be interpreted as more discretionary selling, but insider sales still frequently reflect diversification or liquidity needs.

Key entities

  • Fortrea Holdings Inc.

    Subject of the Form 4 insider sale disclosure (FTRE).

  • Thakral Anshul

    Fortrea CEO and director who sold shares via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FTREMed

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) shares rose 2.8% after acquiring Worldwide Clinical Trials' Early Phase Services division, expanding its clinical research capabilities. The acquisition includes facilities in Texas. Fortrea's stock is volatile, with a 52-week high of $20.70. Q3 revenue was $701.3M, beating estimates, but earnings missed. Full-year revenue guidance was raised to $2.73B.

$FTREHigh

Fortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.